Therapeutic effect of TACE combined with MWA on primary liver cancer

Abstract

Abstract: Objective To observe the therapeutic effect of combining transcatheter arterial chemoembolization (TACE) with ultrasound-guided microwave ablation (MWA) in the treatment of primary liver cancer.Methods We collected data from 96 cases of single primary hepatocellular carcinoma in our hospital over the past two years. In the control group, 46 cases were treated with transcatheter arterial chemoembolization. In the treatment group, 50 cases were treated with transcatheter arterial chemoembolization and ultrasound-guided microwave ablation. We not only compared changes in serum total bilirubin (TBil), alanine aminotransferase (ALT), glutamic grass, transaminase (AST), serum alpha fetoprotein (AFP) before and after surgery, but also analyzed and recurrence of hepatocellular carcinoma within one year.Results The treatment group showed a significant decrease in serum AFP levels and a lower recurrence rate of hepatocellular carcinoma within one year (18.00%) compared to the control group (89.13%) (χ²=48.56, P< 0.05). The levels of serum TBil (t=0.065, P>0.05), ALT (t=0.079, P>0.05) and AST (t=0.076, P>0.05) were similar in both groups when undergoing hepatoprotective treatment.Conclusion The combined treatment of hepatic artery chemoembolization and ultrasound-guided microwave ablation yields significantly better curative results compared to simple hepatic artery chemoembolization, with little influence on liver function. However, patients selection plays a crucial role. It is recommended to perform thorough ablation at one time to minimize risk of intrahepatic and extrahepatic metastasis.

Key words: Liver cancer, Microwave ablation, Transcatheter arterial chemoembolization

ZHANG Xiao-yu, XU Chun-yang, YAO Yu, DAI Feng, ZANG Zhi-dong. Therapeutic effect of TACE combined with MWA on primary liver cancer[J]. Chinese Hepatolgy, 2023, 28(11): 1328-1330.

References

[1] Vogl TJ, Nour-Eldin NA, Hammerstingl RM, et al. Microwave abla-tion (MWA): basics, technique and results in primary and meta-static liver neoplasms-review article. Rofo,2017,189(11):1055-1066.
[2] Abdelaziz AO, Nabeel MM, Elbaz TM, et al. Microwave ablation versus transarterial chemoembolization in large hepatocellular carcinoma:prospective analysis. Scand J Gastroenterol,2015,50(4):479.
[3] 侯玉虎, 马淑梅. 超声造影在肝癌微波消融治疗中的应用现状及进展. 中国现代医药杂志,2016,18(9):106-108.
[4] Liu Z, Zhou Y, Zhang P, et al. Meta-analysis of the therapeutic effect of hepatectomy versus radiofrequency ablation for the treatment of hepatocellular carcinoma. Surg Laparosc Endosc Percutan Tech.2010;20:130-140.
[5] Yang W, Yan K, Goldberg SN, et al. Ten-year survival of hepatocellular carcinoma patients undergoing radiofrequency ablation as a first-line treatment. World J Gastroenterol.2016;22:2993-3005.
[6] 李凤鸣, 陈福真, 李文岗. 肝癌消融治疗的进展. 世界华人消化杂志,2017,25(27):2427-2432.
[7] Sun AX, Cheng ZL, Wu PP, et al. Clinical outcome ofmedium-sized hepatocellular carcinoma treatedwith microwave ablation. World J Gastroenterol,2015;21:2997-3004
[8] Ziemlewicz TJ, Hinshaw JL, Lubner MG, et al. Percutaneous microwave ablation ofhepatocellular carcinoma with a gas-cooledsystem: initial clinical results with 107 tumors. JVasc Interv Radiol,2015;26:62-68.
[9] Liang P, Yu J, Yu XL, et al. Percutaneous cooled-tip microwave ablationunder ultrasound guidance for primary livercancer: a multicentre analysis of 1363 treatment-naive lesions in 1007 patients in China. Gut,2012;61:1100-1101.
[10] 黄书明, 陈圣开, 张涛, 等. 巨大肝癌肝动脉栓塞化疗联合微波消融的临床分析. 重庆医学,2015,1(36):5149-5152.
[11] 常鹏, 张洪义, 肖梅, 等. 肝动脉化疗栓塞术联合微波消融治疗原发性大肝癌疗效观察. 山东医药,2015,11(7):51-53.

[1]	CHEN Zong-jie, PENG Xin-jian, WANG Yu-lin, HU Tian-song. Assessing the prognostic significance of tumor growth rate in patients with huge hepatocellular carcinoma undergoing transcatheter arterial chemoembolization [J]. Chinese Hepatolgy, 2024, 29(1): 85-90.
[2]	CHEN Xiu-feng, JIANG Li-ping, SHEN Ling. Analysis of the effect of TACE combined with PMCT in patients with advanced liver cancer [J]. Chinese Hepatolgy, 2023, 28(9): 1068-1071.
[3]	WANG Kai-li, HU Xiao-wei, YIN Jian, LIU Qing-yang, WANG Qiu-bo. Diagnosis and evaluation of serum midkine levels in response to TACE treatment in patients with hepatocellular carcinoma [J]. Chinese Hepatolgy, 2023, 28(9): 1072-1074.
[4]	LI Ming, JIANG Zhu-chun, SHI Yong-gang, DONG Shi-liang, HE Zi-huai, PAN Mei-fang. Evaluation of the therapeutic effect of transcatheter hepatic artery chemoembolization combined with large segment three-dimensional conformal radiotherapy on unresectable primary liver cancer [J]. Chinese Hepatolgy, 2023, 28(9): 1079-1083.
[5]	LI Jiao-jiao, ZHAO Yong-chang, WU Jun-xia. The T lymphocyte and NK cell levels in patients with malignant pleural effusion after radical resection of primary hepatocellular carcinoma [J]. Chinese Hepatolgy, 2023, 28(8): 924-927.
[6]	WANG Chun-hong, FENG Wei-wei, ZHANG Jing, SI Chen-fei. A clinical study for the therapeutic effect of arotinib on patients with stage III primary liver cancer after interventional therapy [J]. Chinese Hepatolgy, 2023, 28(8): 928-931.
[7]	ZHANG Hai-rong, LI Jin-song, TIAN Xiu-li, HE Xin, JIANG Jue. A novel treatment on small hepatocellular carcinoma adjacent to large vessels by ultrasound assisted precision microwave ablation [J]. Chinese Hepatolgy, 2023, 28(8): 932-934.
[8]	CHEN Yong-ying, PENG Pan, XU Lei-lei. Application of SVM prediction model in judging the degree of pathological differentiation of primary hliver cancerepatocellular carcinoma [J]. Chinese Hepatolgy, 2023, 28(7): 785-788.
[9]	HONG Han, XU Min-hui, JIN Zheng-kang, LI Gao-chao, XU Xiao-yong. The application of hemihepatic blood flow occlusion combined with intermittent Pringle method in the resection of giant liver cancer [J]. Chinese Hepatolgy, 2023, 28(6): 668-672.
[10]	YANG Li-yue, YANG Xiao-liang, YIN Hui-kang. Application of MRI Dual Lava early and late arterial phases combined with portal phase contrast-enhanced scanning in the diagnosis of liver cancer [J]. Chinese Hepatolgy, 2023, 28(6): 673-675.
[11]	XU Zheng-ju, LIU Hui-guo, YAN Yan-yan, YE Qiao-xia, ZHANG Xiao-man, HUANG Jin-fa, LI Yong-fei, WU Jin-piao. Effect of microwave ablation on serum levels of Golgi protein 73 and alpha fetoprotein in patients with primary liver cancer [J]. Chinese Hepatolgy, 2023, 28(5): 554-558.
[12]	ZHU Ye-chen, GENG Cheng-jun, YIN Hui-kang, LI Ya-nan, FENG Quan-ye. The application of three-dimensional reconstruction in the evaluation of vascular system of primary liver cancer before TACE intervention [J]. Chinese Hepatolgy, 2023, 28(5): 559-563.
[13]	MAO Zhen-zhou, LI Fan, ZHANG Zhe-zhe, FENG Yu, DU Bing-jie. Cox regression analysis of the factors affecting the prognosis of liver cancer patients after total caudate lobectomy [J]. Chinese Hepatolgy, 2023, 28(5): 564-567.
[14]	QIN Xiao-ping, ZHANG Jing, AI Ping. The expression of TREM-1, sCD163 and sB7-H3 in patients with primary liver cancer [J]. Chinese Hepatolgy, 2023, 28(4): 461-464.
[15]	LI Hai-xia, WANG Xiu-xiang, GUO Lin, CHAI Mei, LI Yuan-yuan, GAO Ai-hua, SONG Zhao-wei. Effect of microwave ablation combined with DEB-TACE on immune function and prognosis of patients with advanced hepatocellular carcinoma [J]. Chinese Hepatolgy, 2023, 28(4): 465-468.